
Catch up on what happened in optometry during the week of August 7-August 11.

An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.

The investigators explored the effects of the following covariates on development of AMD: sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.

This new technology incorporates a torque management system and wavefront-based technology.

Doctors should consider a few key points before writing a prescription.

Arshad M. Khanani, MD, MA, FASRS, sat down with Optometry Times to discuss the recent FDA approval of avacincaptad pegol intravitreal solution for treatment of geographic atrophy.

The AOA joins several industry leaders in taking the pledge to increase opportunities for Black optometrists and students


Canadian and Australian ophthalmologists and optometrists are looking ahead at the impact increased wildfire smoke can have on the ocular surface.

Drs Chous and Nichols discuss an overview of EyeCon, which will be held December 1 to 2, 2023, in Sanibel Harbour, Florida.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

Managing patient expectations is key to selecting the best lens

According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two phase 3 clinical trials.

Catch up on what happened in optometry during the week of July 24-July 28.

Johnson & Johnson Vision’s ACUVUE Abiliti brand announces its back-to-school campaign to inform parents about myopia and the growing risk of the disease

Results from a study have found that patients who wear scleral contact lenses have a slight increase in IOP.

Euclid Vision and Visionary Optics are offering 6 scholarships intended to support eye care providers in training.

Current, Relevant, Useful 2023 symposium comes to Napa Valley, California.

Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).

The 2023 CRU Eye Symposium in Napa Valley brings exciting presentation topics, including the retina and genetic testing.

Spectacle independence, nighttime glare symptoms often are key factors.

This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.

Unpacking the connection between type 2 diabetes and Alzheimer disease.

Catch up on what happened in optometry during the week of July 24-July 28.

Dr Selina McGee, OD, FAAO, Dipl ABO, met with Optometry Times to discuss the recent FDA approval of XDEMVY, a treatment for Demodex blepharitis, from Tarsus Pharmaceuticals.

Hear from A. Paul Chous, OD, MA, FAAO, and what to look forward to during the 2023 EyeCon meeting December 1-2 in Sanibel Harbour, FL.

CRU 2023 will cover a host of topics, including a co-led presentation by Drs Deborah Jacobs and Melissa Barnett on the latest advancements in the contact lens field.

A review of Demodex mites.

Opthea’s lead biologic drug candidate OPT-302, which is under investigation for the treatment of wet AMD, received nonproprietary drug name sozinibercept, which is a critical step in the FDA approval process.

David Elliott, PhD, FCOptom, FAAO, comes to Optometry and Vision Science after over a decade of leading the success of Ophthalmic & Physiological Optics.